(Paris:VLA),(Paris:VLAP), Total Revenues of EUR174.7 million in line with guidance, including EUR157.9 million in product sales Strong year-end cash position of EUR109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year Chief Executive Officer's […]